奥泰生物(688606) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 reached RMB 91,130.05 million, representing a 5.16% increase compared to the previous year[3] - Net profit attributable to shareholders of the parent company was RMB 21,828.01 million, a decrease of 27.83% year-on-year[3] - Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was RMB 15,524.62 million, down 34.64% from the previous year[3] - Operating profit decreased by 27.72% to RMB 24,974.78 million compared to the previous year[3] - Basic earnings per share decreased by 28.01% to RMB 2.75[3] - The weighted average return on net assets decreased by 2.23 percentage points to 5.58%[3] Assets and Equity - Total assets at the end of the reporting period were RMB 424,862.06 million, an increase of 1.50% from the beginning of the period[4] - Shareholders' equity attributable to the parent company increased by 1.57% to RMB 394,449.65 million[4] Cost and Investment Factors - The decline in profitability was attributed to increased R&D and sales costs, product price declines, and rising financial expenses[6][7] - The company continues to invest in new technology platforms and expand domestic and international market registrations[5]